Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
CD6-R52H9 | Rat | Rat B7-2 / CD86 Protein, His Tag |
|
||
CD6-H82F5 | Human | Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag™, premium grade |
|
||
CD6-M52H0 | Mouse | Mouse B7-2 / CD86 Protein, His Tag (MALS verified) |
|
||
CD6-M5251 | Mouse | Mouse B7-2 / CD86 Protein, Fc Tag (MALS verified) |
|
||
CD6-C5254 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag |
|
||
CD6-C52H5 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified) |
|
||
CD6-H5223 | Human | Human B7-2 / CD86 Protein, His Tag (MALS verified) |
|
||
CD6-H5257 | Human | Human B7-2 / CD86 Protein, Fc Tag, premium grade |
|
Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).
Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | United States | Rejection of renal transplantation | Bristol-Myers Squibb Company | 2011-06-15 | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Proteinuria; Pancreatic neuroendocrine tumors (pNET); Arthritis, Rheumatoid; Delayed Graft Function; Rejection of organ transplantation; Rejection in heart transplantation; Kidney Failure, Chronic | Details |
Abatacept | ONO-4164SC; BMS-188667SC; ONO-4164; BMS-188667 | Approved | Bristol-Myers Squibb Company | Orencia, 恩瑞舒 | United States | Arthritis, Rheumatoid | Bristol-Myers Squibb Company | 2005-12-23 | Arthritis, Psoriatic; Uveitis; Inflammation; Granulomatous Disease, Chronic; Urticaria; Asthma; Sjogren-Larsson Syndrome; Cardiovascular Diseases; Colitis, Ulcerative; Muscular Diseases; Glomerulosclerosis, Focal Segmental; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Anemia, Aplastic; Nephrosis, Lipoid; Mucopolysaccharidosis I; Shwachman-Diamond Syndrome; Scleroderma, Diffuse; Common Variable Immunodeficiency; Arthralgia; Arthritis; Myocarditis; Eye Diseases; Lymphohistiocytosis, Hemophagocytic; Leukocyte-Adhesion Deficiency Syndrome; Nephrotic Syndrome; Crohn Disease; Anemia, Sickle Cell; Thrombasthenia; Behcet Syndrome; Vitiligo; Kostmann Syndrome; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Giant Cell Arteritis; Immunoglobulin G4-Related Disease; Alopecia Areata; Dermatomyositis; Myositis; Multiple Sclerosis, Relapsing-Remitting; Myasthenia Gravis; Anemia, Diamond-Blackfan; Granulomatosis with Polyangiitis; Hematologic Diseases; Polychondritis, Relap | Details |
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | United States | Rejection of renal transplantation | Bristol-Myers Squibb Company | 2011-06-15 | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Proteinuria; Pancreatic neuroendocrine tumors (pNET); Arthritis, Rheumatoid; Delayed Graft Function; Rejection of organ transplantation; Rejection in heart transplantation; Kidney Failure, Chronic | Details |
Abatacept | ONO-4164SC; BMS-188667SC; ONO-4164; BMS-188667 | Approved | Bristol-Myers Squibb Company | Orencia, 恩瑞舒 | United States | Arthritis, Rheumatoid | Bristol-Myers Squibb Company | 2005-12-23 | Arthritis, Psoriatic; Uveitis; Inflammation; Granulomatous Disease, Chronic; Urticaria; Asthma; Sjogren-Larsson Syndrome; Cardiovascular Diseases; Colitis, Ulcerative; Muscular Diseases; Glomerulosclerosis, Focal Segmental; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Anemia, Aplastic; Nephrosis, Lipoid; Mucopolysaccharidosis I; Shwachman-Diamond Syndrome; Scleroderma, Diffuse; Common Variable Immunodeficiency; Arthralgia; Arthritis; Myocarditis; Eye Diseases; Lymphohistiocytosis, Hemophagocytic; Leukocyte-Adhesion Deficiency Syndrome; Nephrotic Syndrome; Crohn Disease; Anemia, Sickle Cell; Thrombasthenia; Behcet Syndrome; Vitiligo; Kostmann Syndrome; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Giant Cell Arteritis; Immunoglobulin G4-Related Disease; Alopecia Areata; Dermatomyositis; Myositis; Multiple Sclerosis, Relapsing-Remitting; Myasthenia Gravis; Anemia, Diamond-Blackfan; Granulomatosis with Polyangiitis; Hematologic Diseases; Polychondritis, Relap | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ORCA-010 | ORCA-010 | Phase 2 Clinical | Orca Therapeutics Bv | Prostatic Neoplasms | Details |
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Abatacept biosimilar (Dr. Reddy's Laboratories) | DRL-AB | Phase 1 Clinical | Dr.Reddy's Laboratories Ltd | Arthritis, Rheumatoid | Details |
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid | Details | |
ORCA-010 | ORCA-010 | Phase 2 Clinical | Orca Therapeutics Bv | Prostatic Neoplasms | Details |
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Abatacept biosimilar (Dr. Reddy's Laboratories) | DRL-AB | Phase 1 Clinical | Dr.Reddy's Laboratories Ltd | Arthritis, Rheumatoid | Details |
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.